Cargando…
An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations
The worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has urged scientists to present some novel vaccine platforms during this pandemic to provide a rather prolonged immunity against this respiratory viral infection. In spite of many campaigns formed against the admini...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968612/ https://www.ncbi.nlm.nih.gov/pubmed/36867924 http://dx.doi.org/10.1016/j.intimp.2023.109934 |
_version_ | 1784897536257949696 |
---|---|
author | Mirtaleb, Mona Sadat Falak, Reza Heshmatnia, Jalal Bakhshandeh, Behnaz Taheri, Ramezan Ali Soleimanjahi, Hoorieh Zolfaghari Emameh, Reza |
author_facet | Mirtaleb, Mona Sadat Falak, Reza Heshmatnia, Jalal Bakhshandeh, Behnaz Taheri, Ramezan Ali Soleimanjahi, Hoorieh Zolfaghari Emameh, Reza |
author_sort | Mirtaleb, Mona Sadat |
collection | PubMed |
description | The worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has urged scientists to present some novel vaccine platforms during this pandemic to provide a rather prolonged immunity against this respiratory viral infection. In spite of many campaigns formed against the administration of mRNA-based vaccines, those platforms were the most novel types, which helped us meet the global demand by developing protection against COVID-19 and reducing the development of severe forms of this respiratory viral infection. Some societies are worry about the COVID-19 mRNA vaccine administration and the potential risk of genetic integration of inoculated mRNA into the human genome. Although the efficacy and long-term safety of mRNA vaccines have not yet been fully clarified, obviously their application has switched the mortality and morbidity of the COVID-19 pandemic. This study describes the structural features and technologies used in producing of COVID-19 mRNA-based vaccines as the most influential factor in controlling this pandemic and a successful pattern for planning to produce other kind of genetic vaccines against infections or cancers. |
format | Online Article Text |
id | pubmed-9968612 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99686122023-02-27 An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations Mirtaleb, Mona Sadat Falak, Reza Heshmatnia, Jalal Bakhshandeh, Behnaz Taheri, Ramezan Ali Soleimanjahi, Hoorieh Zolfaghari Emameh, Reza Int Immunopharmacol Article The worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has urged scientists to present some novel vaccine platforms during this pandemic to provide a rather prolonged immunity against this respiratory viral infection. In spite of many campaigns formed against the administration of mRNA-based vaccines, those platforms were the most novel types, which helped us meet the global demand by developing protection against COVID-19 and reducing the development of severe forms of this respiratory viral infection. Some societies are worry about the COVID-19 mRNA vaccine administration and the potential risk of genetic integration of inoculated mRNA into the human genome. Although the efficacy and long-term safety of mRNA vaccines have not yet been fully clarified, obviously their application has switched the mortality and morbidity of the COVID-19 pandemic. This study describes the structural features and technologies used in producing of COVID-19 mRNA-based vaccines as the most influential factor in controlling this pandemic and a successful pattern for planning to produce other kind of genetic vaccines against infections or cancers. Elsevier B.V. 2023-04 2023-02-27 /pmc/articles/PMC9968612/ /pubmed/36867924 http://dx.doi.org/10.1016/j.intimp.2023.109934 Text en © 2023 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Mirtaleb, Mona Sadat Falak, Reza Heshmatnia, Jalal Bakhshandeh, Behnaz Taheri, Ramezan Ali Soleimanjahi, Hoorieh Zolfaghari Emameh, Reza An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations |
title | An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations |
title_full | An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations |
title_fullStr | An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations |
title_full_unstemmed | An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations |
title_short | An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations |
title_sort | insight overview on covid-19 mrna vaccines: advantageous, pharmacology, mechanism of action, and prospective considerations |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968612/ https://www.ncbi.nlm.nih.gov/pubmed/36867924 http://dx.doi.org/10.1016/j.intimp.2023.109934 |
work_keys_str_mv | AT mirtalebmonasadat aninsightoverviewoncovid19mrnavaccinesadvantageouspharmacologymechanismofactionandprospectiveconsiderations AT falakreza aninsightoverviewoncovid19mrnavaccinesadvantageouspharmacologymechanismofactionandprospectiveconsiderations AT heshmatniajalal aninsightoverviewoncovid19mrnavaccinesadvantageouspharmacologymechanismofactionandprospectiveconsiderations AT bakhshandehbehnaz aninsightoverviewoncovid19mrnavaccinesadvantageouspharmacologymechanismofactionandprospectiveconsiderations AT taheriramezanali aninsightoverviewoncovid19mrnavaccinesadvantageouspharmacologymechanismofactionandprospectiveconsiderations AT soleimanjahihoorieh aninsightoverviewoncovid19mrnavaccinesadvantageouspharmacologymechanismofactionandprospectiveconsiderations AT zolfaghariemamehreza aninsightoverviewoncovid19mrnavaccinesadvantageouspharmacologymechanismofactionandprospectiveconsiderations AT mirtalebmonasadat insightoverviewoncovid19mrnavaccinesadvantageouspharmacologymechanismofactionandprospectiveconsiderations AT falakreza insightoverviewoncovid19mrnavaccinesadvantageouspharmacologymechanismofactionandprospectiveconsiderations AT heshmatniajalal insightoverviewoncovid19mrnavaccinesadvantageouspharmacologymechanismofactionandprospectiveconsiderations AT bakhshandehbehnaz insightoverviewoncovid19mrnavaccinesadvantageouspharmacologymechanismofactionandprospectiveconsiderations AT taheriramezanali insightoverviewoncovid19mrnavaccinesadvantageouspharmacologymechanismofactionandprospectiveconsiderations AT soleimanjahihoorieh insightoverviewoncovid19mrnavaccinesadvantageouspharmacologymechanismofactionandprospectiveconsiderations AT zolfaghariemamehreza insightoverviewoncovid19mrnavaccinesadvantageouspharmacologymechanismofactionandprospectiveconsiderations |